MedTrace Logo

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

NCT02393703 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 181

Last updated 2026-02-09

No results posted yet for this study

Summary

The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients. The results of this study will be the basis for future studies exploring this area.

Conditions

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Pittsburgh

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • William Jarnagin, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393703 on ClinicalTrials.gov